Randomized Double Blind Placebo Controlled Trial of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis
Phase of Trial: Phase II/III
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 03 Apr 2018 Status changed from recruiting to completed.
- 03 May 2017 Planned End Date changed from 1 Oct 2018 to 1 Mar 2019.
- 03 May 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2018.